Seamless Execution Across Early-Phase Alzheimer’s Trials

July 15, 2025

In the face of pandemic-era recruitment barriers and aggressive timelines, CRC partnered with a sponsor developing a novel Alzheimer’s treatment to support three early-phase trials—advancing the program from first-in-human (FIH) to long-term safety evaluation.


Across all three studies, CRC delivered consistent communication, high-touch site engagement, and trusted operational oversight to keep the program moving forward:


  • Trial A: Phase I FIH study in healthy volunteers (47 subjects, 1 site)
  • Trial B: Phase Ib/IIa study in Alzheimer’s patients (158 subjects, 18 sites)
  • Trial C: Phase II OLE in rollover and de novo patients (121 subjects, 13 sites)


Despite compressed SAD/MAD timelines, turnover among vendor staff, and participant hesitations during COVID-19, CRC ensured on-time and on-budget completion—positioning the sponsor to move confidently into the next phase of development.

Facing tight clinical timelines? Let’s talk.

< Older Post
Illustration of active brain neurons highlighting neural pathways

The Expanding Role of GLP-1 Receptor Agonists in CNS Clinical Research

July 1, 2025
GLP-1 receptor agonists may offer a new path for treating addiction and mental health challenges, emerging as a versatile class in CNS clinical research.
Principal investigator and clinical research associate

4 Ways Strategic Site Selection Maximizes the Value Equation

April 10, 2025
In clinical trials, success hinges not just on protocol design and quality data but on choosing the right investigative sites and engaging them effectively. Here are four key reasons why strategic site selection is critical for maximizing value in your clinical trials.
A car is driving through a tunnel at night.

Expedited Completion of a Complex Driving Study

March 26, 2025
Discover how CRC leveraged our proprietary driving simulator to swiftly complete a next-day effects study in support of a multinational Pharma Company's NDA submission. This case study showcases our ability to navigate complex clinical challenges under tight timelines, finishing 11 days ahead of schedule and exceeding project expectations.
Show More